3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasm Metastasis
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Camurati-Engelmann Syndrome
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Melanoma
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Interventions
Gemcitabine
157
Cisplatin
116
pembrolizumab
80
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Cystectomy
40
Docetaxel
38
atezolizumab
33
Magnetic Resonance Spectroscopy
31
durvalumab
30
Radiotherapy
29
BCG Vaccine
26
avelumab
24
Specimen Handling
24
Doxorubicin
23
enfortumab vedotin
22
Fluorouracil
20
Cystoscopy
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Filgrastim
14
Transurethral Resection of Bladder
13
Sunitinib
13
Ipilimumab
13
vinflunine
12
5-aminolevulinic acid hexyl ester
12
tremelimumab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Neoplasms
×
bintrafusp alfa protein, human
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled